Medplus Health Services Limited has announced the release of pledged shares by its promoter entity Agilemed Investments Private Limited following successful debt repayment. The company filed the regulatory disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 31, marking the completion of its debt refinancing initiative.

Share Pledge Release Details

Agilemed Investments Private Limited released 41,71,970 equity shares from pledge arrangements on December 24. The release was executed following repayment of existing debt obligations to multiple lenders including Catalyst Trusteeship Limited and Modulus Alternatives Investment Managers Limited.

Updated Promoter Shareholding Structure

Following the pledge release, the promoter group's encumbrance profile has been significantly reduced. The total promoter shareholding remains stable at 40.29% while the pledged portion has decreased substantially.

Debt Refinancing Framework

The share pledge release represents the successful completion of the debt refinancing framework involving non-convertible debentures. The arrangement included multiple financial instruments with structured repayment mechanisms to debenture trustees and lenders.

Regulatory Compliance and Impact

The company has fulfilled all disclosure requirements under SEBI regulations with comprehensive documentation filed on December 31, 2025. The encumbrance release demonstrates improved financial flexibility at the promoter level while maintaining strategic control over the healthcare retail chain.

The successful debt repayment and consequent pledge release reflects the company's strengthened financial position. This development provides enhanced operational flexibility to the promoter group while reducing overall leverage in the shareholding structure of Medplus Health Services Limited.

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, received a drug license suspension order from the Assistant Director of Drugs Control Administration in Rangareddy, Telangana.

Regulatory Action Details

The suspension order specifically targets one store situated at Vanasthalipuram Ganesh Temple in Telangana. The regulatory action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of approximately ₹1.19 lakhs due to the one-day suspension of the drug license.

Regulatory Compliance

The disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has fulfilled its obligation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company Communication

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on the websites of BSE Limited and National Stock Exchange of India Limited. The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on December 31, 2025.